BioCryst Pharmaceuticals, Inc. announced the appointment of Sandeep M. Menon, MD, PhD, as Chief Research and Development Officer. Dr. Menon joins BioCryst from Alnylam Pharmaceuticals, where he served as Chief Development Officer, overseeing global clinical development and safety across a broad portfolio spanning multiple therapeutic areas. Under his leadership, his team read out and secured FDA approval of AMVUTTRA (vutrisiran), a novel RNAi therapeutic for ATTR cardiomyopathy, and advanced multiple programs through key clinical milestones.
Previously, Dr. Menon spent over a decade at Pfizer in senior R&D leadership roles, most recently as Senior Vice President, Head of Early Clinical Development and Chief Scientific Officer, BioMedicine AI and Digital Sciences. He led large, global development organizations and played a key role in improving R&D success rates across the portfolio. He co-led the clinical development of PAXLOVID, which progressed from first-in-human dosing to emergency use authorization in nine months, and contributed to the development and approval of multiple therapies across oncology, immunology and rare disease.
Earlier in his career, Dr. Menon held clinical development and biostatistics leadership roles at Biogen Idec and Aptiv Solutions (ICON). Dr. Menon holds a PhD in Biostatistics and an MPH in Epidemiology and Biostatistics from Boston University, an MS in Translational Pharmacology from The Ohio State University, and a medical degree from Karnataka University in India.
